Aegis COVID-19 Testing
8/13/20 - HHS Announces collaboration with Aegis Sciences Corporation to ramp high quality COVID-19 RT-PCR testing with fast results. Click the link for more information https://www.hhs.gov/about/news/2020/08/13/hhs-invests-in-diagnostic-labs-to-expand-covid-19-testing-capacity-in-the-united-states.html
- For inquiries concerning Aegis’s collaboration with HHS, and/or testing for federal, state, and local governmental entities, please contact Joel Galanter, Chief Legal Officer (615-577-4509), email@example.com
- For inquiries concerning COVID-19 testing needs for clinical entities, universities/schools, employers etc., please contact Mike Ziegler, Chief Sales Officer (803-431-6178), firstname.lastname@example.org or Regina Sweeney, Vice President Client Relations (615-308-6302), email@example.com
07/10/20 - Aegis Sciences Corporation – Testing Demand, Capacity, New Customer Update. Click Here for more information.
Testing Demand, Capacity, and Aegis’s Response
Aegis has performed hundreds of thousands of COVID-19 molecular diagnostic tests since launching its qPCR test in April. With an original capacity of 3,500 tests per day, Aegis has increased capacity to over 10,000 tests per day and is in the process of expanding to over 14,000 tests per day by the end of the month. We are also actively engaged in planning further capacity expansion in August and beyond.
Thanks to the diligent efforts of our expert laboratory science and operations teams, we have been able to maintain a rapid turnaround time in an average of 24-hours despite significant demand. With the increase in cases nationwide, however, we have experienced a spike in demand over the past three weeks from existing customer accounts and new customer accounts. Given the clinical and public health importance of providing rapid, accurate test results, we have put a temporary hold on accepting new customer accounts. While this is a difficult decision, we believe this action is necessary to ensure we maintain clinically relevant service levels by resulting tests within 24-48 hours and continue to meet our commitments to existing customers and their patients.
As our capacity expands later this month through additions to our physical space and instrumentation, as well as through efficiency gains, Aegis is confident we will be able to continue meeting our service commitments to existing customer accounts and also begin again adding new customer accounts in the coming weeks. We will diligently continue responding to this public health emergency with all our resources and capabilities.
04/27/2020 - Aegis Sciences Corporation Doubles Capacity for Coronavirus Disease 2019 (COVID-19) Testing. Capacity for 7,000 tests a day begins May 4 in response to community need. Read full press release
04/13/2020 - Aegis launches test for Coronavirus disease 2019 (COVID-19). Our dedicated team of lab scientists has worked diligently to leverage Aegis’s strong lab capabilities and moved quickly to offer this valuable diagnostic tool to aid in the fight against COVID-19. Capacity for 3,500 tests a day beginning April 15, 2020; results available within 24 hours. Read full press release
04/15/20 - Notice to Health Plans, Patients, and Governmental Entities –Pricing and Coding for Aegis COVID-19 (SARS-CoV-2, qPCR) Testing – Effective 04/15/2020
- Pricing: $100 per test (same for all CPT codes)
- Coding: U0003
On April 14th, Centers for Medicare and Medicaid Services (CMS) announced new procedure codes and associated pricing for COVID-19 testing performed utilizing high-throughput technologies capable of processing large volumes of COVID-19 tests rapidly. CMS took this action in light of the high cost of resources, required investment, and advanced technical requirements associated with utilizing high-throughput technologies. All of Aegis’s COVID-19 tests are performed utilizing advanced high-throughput platforms. Aegis will continue to align with the floor pricing established by CMS, which is $100 for Aegis’s test, and accept that amount as payment for its COVID-19 testing.
04/16/2020 - Aegis Sciences gears up for COVID-19 testing. Featured on WSMV News4 Nashville - View Clip
Downstream effects of COVID-19 on your patients
Date and Time:
Length: 30 minutes
If you are a patient that had COVID-19 testing performed by Aegis Sciences click below to retrieve your results:
COVID-19 Testing FAQs
Aegis’ COVID-19 testing FAQ provides information specific to our lab’s testing capabilities. Additionally, the FAQ document summarizes pertinent information from various resources leading the fight against the COVID-19 pandemic.
Specimen Collection Instructions
Patient Fact Sheet
This Fact Sheet contains information to help you understand the risks and benefits of using this test for the diagnosis of COVID-19. After reading this Fact Sheet, if you have questions or would like to discuss the information provided, please talk to your healthcare provider.
Provider Fact Sheet
This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of a Molecular Laboratory Developed Test (LDT) COVID-19 Authorized Test (Molecular LDT COVID-19 Authorized Test) that has been issued an Emergency Use Authorization (EUA) by FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider.